Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | F2 | P00734 | 1/20 | 0.65 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2233431 | 1.00 | F10 (0.67) | F10ABCB11F2ST14PTGS2 | |
| SCHEMBL3276611 | 1.00 | F10 (0.67) | F10ABCB11F2ST14PTGS2 | |
| SCHEMBL14838626 | 0.90 | F10 (0.67) | F10ABCB11F2ST14PTGS2 | |
| SCHEMBL10001459 | 0.89 | F10 (0.65) | F10ABCB11F2ST14PTGS2 | |
| SCHEMBL25518142 | 0.88 | F10 (0.55) | F10ABCB11F2ST14PTGS2 | |
| SCHEMBL78973 | 0.88 | F10 (0.62) | F10ABCB11F2ST14 | |
| SCHEMBL2995671 | 0.88 | F10 (0.59) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL2995676 | 0.88 | F10 (0.59) | F10ABCB11F2ST14CYP3A4 | |
| SCHEMBL78814 | 0.87 | F10 (0.62) | F10ABCB11F2ST14 | |
| SCHEMBL77157 | 0.86 | F10 (0.50) | F10ABCB11F2ST14PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218145-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN | RANBAXY LABORATORIES LIMITED (IN) | 2015-08-06 | — | — | US | claimed |
| EP-2900663-A2 | PROCESS FOR THE PREPARATION OF RIVAROXABAN | Ranbaxy Laboratories Limited (IN) | 2015-08-05 | — | — | EP | claimed |
| WO-2013098833-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2013-07-04 | — | — | WO | claimed |
| US-20100081807-A1 | METHOD FOR PRODUCING 5-CLORO-N-(METHYL)-2-THIOPHENECARBOXAMIDE | BAYER HEALTHCARE AG (DE) | 2010-04-01 | — | — | US | claimed |
| US-20070149522-A1 | Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide | BAYER HEALTHCARE AG (DE) | 2007-06-28 | — | — | US | claimed |
| WO-2023088229-A1 | METHOD FOR SYNTHESIZING RIVAROXABAN | 浙江华海药业股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20170267669-A1 | Process for the Preparation of Rivaroxaban | CIPLA LIMITED (IN) | 2017-09-21 | — | — | US | disclosed |
| US-9556163-B2 | Process for the preparation of a rivaroxaban and intermediates formed in said process | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2017-01-31 | — | — | US | disclosed |
| EP-2895176-B1 | RIVAROXABAN INTERMEDIATE AND PREPARATION THEREOF | WANBURY LTD (IN) | 2016-10-19 | — | — | EP | disclosed |
| US-9394292-B2 | Rivaroxaban intermediate and preparation thereof | WANBURY LTD. (IN) | 2016-07-19 | — | — | US | disclosed |
| US-9394292-B2 | Rivaroxaban intermediate and preparation thereof | WANBURY LTD. (IN) | 2016-07-19 | — | — | US | disclosed |
| US-20150299175-A1 | RIVAROXABAN INTERMEDIATE AND PREPARATION THEREOF | WANBURY LTD. (IN) | 2015-10-22 | — | — | US | disclosed |
| US-20070149522-A1 | Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide | BAYER HEALTHCARE AG (DE) | 2007-06-28 | — | — | US | disclosed |
| US-7157456-B2 | Anticoagulates for treating cardiovascular disorders, such as myocardial infarct, angina pectoris, restenoses after angioplasty, bypass, stroke; treatment of atherosclerosis, arthritis, Alzheimer's disease or cancer | BAYER HEALTHCARE AG (DE) | 2007-01-02 | — | — | US | disclosed |
| US-20060258724-A1 | Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-16 | — | — | US | disclosed |
| EP-1626969-A1 | HETEROCYCLIC COMPOUNDS | Bayer HealthCare AG (DE) | 2006-02-22 | — | — | EP | disclosed |
| EP-1526132-A2 | Substituted oxazolidinone derivatives and their use as factor xa inhibitors | Bayer HealthCare AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| EP-1261606-B1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| US-20040242660-A1 | Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| WO-2004101557-A1 | HETEROCYCLIC COMPOUNDS | BAYER HEALTHCARE AG (DE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149522-A1 | Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide | NT5C, NOX5, MT-ND5 | F10 4544/4885ABCB11 4723/4885F2 3487/4885 |
| US-20100081807-A1 | METHOD FOR PRODUCING 5-CLORO-N-(METHYL)-2-THIOPHENECARBOXAMIDE | CBR3, NT5C, CBR1 | F10 4090/4885ABCB11 3327/4885F2 3094/4885 |
| US-20170267669-A1 | Process for the Preparation of Rivaroxaban | F7, F5, F2 | F10 10/4885ABCB11 2630/4885F2 3/4885 |
| US-20040242660-A1 | Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders | SERPINC1, XDH, SDHB | F10 41/4885ABCB11 803/4885F2 4/4885 |
| US-20150218145-A1 | PROCESS FOR THE PREPARATION OF RIVAROXABAN | VKORC1L1, PROC, VKORC1 | F10 13/4885ABCB11 3848/4885F2 5/4885 |
| US-20150299175-A1 | RIVAROXABAN INTERMEDIATE AND PREPARATION THEREOF | VKORC1L1, VKORC1, CYP3A5 | F10 27/4885ABCB11 3735/4885F2 11/4885 |
| US-20060258724-A1 | Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation | F2, F11, F13B | F10 9/4885ABCB11 337/4885F2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.